Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Int J Oncol ; 43(1): 151-8, 2013 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-23620085

RESUMO

Gene therapy is a potentially viable approach for treating hormone-refractory prostate cancer (HRPC), it requires efficient delivery systems and a target gene. Inducing carcinoma cell apoptosis by inhibition of heat shock protein 70 (HSP70) overexpression has been emerging as an attractive strategy for cancer therapy. In our study, the high tumor-specificity of human telomerase reverse transcriptase (HTERT) expression prompted the use of an HTERT/cytomegalovirus (CMV) chimeric promoter to drive HSP70-ShRNA expression to induce HRPC 22RV1 cell apoptosis. At the same time, sonoporation induced by ultrasound-targeted microbubble destruction (UTMD) was utilized for delivery of plasmid loaded with HTERT/CMV promoter. Our results indicated the combination of sonoporation, low-dose liposomes and HTERT/CMV chimeric promoter as a delivery system has the potential to promote efficient gene transfer with lower cytotoxicity.


Assuntos
Terapia Genética , Proteínas de Choque Térmico HSP70/genética , Neoplasias da Próstata/genética , Transfecção/métodos , Apoptose , Linhagem Celular Tumoral , Citomegalovirus/genética , Regulação Neoplásica da Expressão Gênica , Vetores Genéticos , Humanos , Lipossomos/administração & dosagem , Masculino , Regiões Promotoras Genéticas , Neoplasias da Próstata/patologia , Neoplasias da Próstata/terapia , RNA Interferente Pequeno , Telomerase/genética
2.
Int J Mol Med ; 31(1): 163-71, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23138749

RESUMO

A potentially viable approach for treating late-stage prostate cancer is gene therapy. Successful gene therapy requires safe and efficient delivery systems. In this study, we report the efficient delivery of small interfering RNA (siRNA) via the use of biodegradable nanoparticles (NPs) made from monomethoxypoly(ethylene glycol)-poly(lactic-co-glycolic acid)-poly-l-lysine (mPEG-PLGA-PLL) triblock copolymers. On the basis of previous findings, cyclic Arg-Gly-Asp (cRGD) peptides were conjugated to NPs to recognize the target site, integrin αvß3, expressed in high levels in PC-3 prostate cancer cells. The suppression of angiogenesis by the downregulation of vascular endothelial growth factor (VEGF) expression has been widely used to inhibit the growth of malignant tumors. In our study, human VEGF (hVEGF)-siRNA was encapsulated in NPs to inhibit VEGF expression in PC-3 cells. Concurrently, sonoporation induced by ultrasound-targeted microbubble destruction (UTMD) was utilized for the delivery of siRNA-loaded NPs. Our results showed low cytotoxicity and high gene transfection efficiency, demonstrating that the targeted delivery of biodegradable NPs with UTMD may be potentially applied as new vector system for gene delivery.


Assuntos
Técnicas de Transferência de Genes , Microbolhas , Nanopartículas/administração & dosagem , RNA Interferente Pequeno/genética , Ultrassom/métodos , Fator A de Crescimento do Endotélio Vascular/genética , Linhagem Celular Tumoral , Regulação para Baixo , Humanos , Oligopeptídeos/metabolismo , Poliésteres/metabolismo , Polietilenoglicóis/metabolismo , RNA Interferente Pequeno/metabolismo , Transfecção , Fator A de Crescimento do Endotélio Vascular/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA